Previous Close | 7.56 |
Open | 7.61 |
Bid | 6.11 x 200 |
Ask | 9.88 x 200 |
Day's Range | 7.61 - 8.52 |
52 Week Range | 7.11 - 15.49 |
Volume | |
Avg. Volume | 33,333 |
Market Cap | 208.134M |
Beta (5Y Monthly) | 0.81 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.35 |
Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.61 |
TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in acc
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists at AUA 2024 — — Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-s
Key Insights Given the large stake in the stock by institutions, Profound Medical's stock price might be vulnerable to...